Durgical
EN
Open the app

Growth factors and marrow stimulants: G-CSF, ESAs, TPO receptor agonists

  • Treatment and support

The body has hormones that tell the marrow to make neutrophils, red cells and platelets. Copies of them can lift a count, but only if the marrow can answer.

Updated

What it is

Haematopoietic growth factors are man-made versions or mimics of the body's signals: granulocyte colony-stimulating factor (G-CSF, such as filgrastim and pegfilgrastim) for neutrophils, erythropoiesis-stimulating agents (ESAs, such as epoetin alfa and darbepoetin alfa) for red cells, and thrombopoietin receptor agonists (romiplostim, eltrombopag, avatrombopag) for platelets. Luspatercept, an erythroid maturation agent, helps red cells in some MDS and thalassaemia. Each shortens or prevents a cytopenia in specific situations; none treats the cause, and each has its own risks.

What to know

  • G-CSF prevents febrile neutropenia when a regimen carries a high risk of it (primary prophylaxis) or after a previous episode (secondary prophylaxis); it also mobilises stem cells for collection and treats severe congenital neutropenia.
  • G-CSF is not given routinely for afebrile neutropenia, and is contraindicated in sickle cell disease, where it can trigger a severe crisis.
  • ESAs treat the anaemia of chronic kidney disease, some chemotherapy-induced anaemia when cure is not the goal, and lower-risk MDS with a low erythropoietin level; iron stores are replete first.
  • ESAs aim for the lowest haemoglobin that avoids transfusion, not a normal one: higher targets raise the risk of stroke, thrombosis and, in some cancers, tumour progression.
  • TPO receptor agonists treat chronic immune thrombocytopenia, are used with immunosuppression in severe aplastic anaemia (eltrombopag) and raise platelets before procedures in chronic liver disease (avatrombopag).
  • Oral eltrombopag binds calcium and other metal ions, so it is taken apart from dairy, antacids and mineral supplements, and the liver tests are followed.

How it is done (and why)

  1. Name the cytopenia and its cause: a growth factor never replaces finding why the count is low.
  2. Check that the marrow can respond: precursors present, no untreated deficiency, iron replete for an ESA.
  3. Match the agent to the goal: fewer infections (G-CSF), fewer transfusions (ESA, luspatercept), fewer bleeds (TPO agonist).
  4. Set a target that removes the danger, not a normal count.
  5. Monitor the count and the specific risks; stop or reduce when the target is reached.
  6. If the response is lost, look for a new cause: iron deficiency, infection, antibodies or disease progression.

Three families of growth factors compared

FeatureG-CSFESAsTPO receptor agonists
Natural signal copiedG-CSF from monocytes and endotheliumErythropoietin from the kidneyThrombopoietin from the liver
Main usesPrevent febrile neutropenia; stem cell mobilisation; congenital neutropeniaAnaemia of CKD; selected chemotherapy-induced anaemia; lower-risk MDSChronic ITP; severe aplastic anaemia; low platelets before procedures in liver disease
Needs firstA regimen with high febrile neutropenia riskIron replete; other causes excludedA confirmed diagnosis; liver tests (eltrombopag)
Main risksBone pain, rare splenic rupture, sickle crisisHypertension, thrombosis, stroke, tumour progression, rare pure red cell aplasiaThrombosis, marrow reticulin fibrosis, rebound low platelets on stopping, liver injury (eltrombopag)
Time to effectDaysWeeksOne to two weeks

Risks and precautions

  • Bone pain after G-CSF is common and expected; left upper quadrant or shoulder-tip pain is not, and needs assessment for splenic enlargement or rupture.
  • A patient with CKD whose haemoglobin stops responding to an ESA usually has iron deficiency, inflammation, bleeding or under-dialysis before anything rarer.
  • Sudden severe anaemia with very low reticulocytes after months of an ESA suggests antibody-mediated pure red cell aplasia: stop the ESA and test.
  • Stopping a TPO agonist abruptly can drop platelets below the starting level; counts are watched for weeks after stopping.
  • G-CSF is avoided in AML and MDS outside specific protocols, and in people with sickle cell disease, including those being mobilised for stem cell collection.

Monitoring and next step

  • G-CSF: full count to confirm recovery; stop when the neutrophils have recovered past the nadir.
  • ESAs: haemoglobin, reticulocytes, ferritin and transferrin saturation before and during treatment; blood pressure at every visit.
  • Loss of ESA response: iron studies, CRP, reticulocytes and, if suspected, anti-erythropoietin antibodies.
  • TPO agonists: weekly platelets until stable, liver tests with eltrombopag, and a smear or marrow review if new abnormal cells appear.
  • Lower-risk MDS: serum erythropoietin level and ring sideroblasts or SF3B1 status help choose between an ESA and luspatercept.

Common traps

  • Starting an ESA without checking iron: the marrow cannot make red cells without fuel, so the response fails
  • Pushing haemoglobin to normal with an ESA: higher targets raise the risk of stroke and thrombosis without extra benefit
  • Giving G-CSF to someone with sickle cell disease: the surge of activated neutrophils can trigger a severe, even fatal, crisis
  • Expecting a growth factor to work in an empty marrow: without precursors, there is nothing for the signal to stimulate
  • Stopping a TPO receptor agonist overnight: platelets can fall below the starting level, so it is tapered and the counts followed

Test yourself

Think of the answer, then tap the question to see it.

A woman on dialysis has a haemoglobin that has stopped rising on an ESA; her ferritin and transferrin saturation are low. What is the next step?

Replace iron, usually intravenously in dialysis, because the marrow lacks fuel; raising the ESA dose instead adds thrombosis and stroke risk without fixing the cause.

A 22-year-old with sickle cell disease is to donate stem cells for a sibling. Why is G-CSF mobilisation avoided?

G-CSF raises and activates neutrophils, which promote sickling and vaso-occlusion; it has caused severe crises and deaths in sickle cell disease.

Why does a TPO receptor agonist work in immune thrombocytopenia even though the platelets are being destroyed?

In ITP, production is also relatively low for the rate of destruction; stimulating megakaryocytes raises output enough to outpace the loss.

A man on eltrombopag takes it with milk at breakfast and his platelets do not rise. What is the likely explanation?

Eltrombopag binds calcium and other metal ions, so taking it with dairy or mineral supplements reduces its absorption; it is taken apart from them.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Filgrastim (StatPearls (NCBI Bookshelf), 2023); Epoetin Alfa (StatPearls (NCBI Bookshelf), 2024); Thrombopoietin Receptor Agonists (StatPearls (NCBI Bookshelf), 2024); Eltrombopag: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.